Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05940896 | RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression | recruiting | Phase 1 | 24 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06144723 | Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 402 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06134531 | First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors | not yet recruiting | Phase 1 | 31 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06132217 | A Study of Simmitinib Plus SG001 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 168 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05866692 | A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 156 | TYK Medicines, IncINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05895825 | A Study of EOC237 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 48 | Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., LtdINDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06112041 | The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) | not yet recruiting | Phase 2 | 29 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06102837 | Tumor Vaccines for Solid Tumors | recruiting | — | 340 | Huashan HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05621486 | A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Shanghai East HospitalOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06072989 | Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors | recruiting | Phase 1 | 24 | Shanghai East HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02193503 | MVX-ONCO-1 in Patients With Solid Tumor | active not recruiting | Phase 1 | 34 | Maxivax SAINDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05947695 | Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer | recruiting | N/A | 100 | Good Samaritan Hospital Medical Center, New YorkOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06028724 | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)(POPCORN) | recruiting | — | 782 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06026501 | A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | not yet recruiting | Phase 1 / Phase 2 | 120 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Sep 7, 2023 | clinicaltrials |
| NCT05631886 | Combination of CAR-DC Vaccine and ICIs in Malignant Tumors | recruiting | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05788107 | Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma | not yet recruiting | Phase 1 | 30 | Shanghai Henlius BiotechINDUSTRY | 0 | Aug 9, 2023 | clinicaltrials |
| NCT04416165 | Comparison of FDG and FAPI in Patients With Various Types of Cancer | recruiting | N/A | 3,000 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05947487 | CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05940116 | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 322 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05911464 | A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 248 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05909436 | Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors | recruiting | Phase 1 / Phase 2 | 107 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05823285 | A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients | recruiting | Phase 1 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05811975 | KSX01-TCRT Injection Project in Solid Tumors | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05361954 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 36 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Apr 12, 2023 | clinicaltrials |
| NCT05804864 | A Study of KM501 in Patients With Solid Tumors | not yet recruiting | Phase 1 | 96 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05204862 | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | TiumBio Co., Ltd.INDUSTRY | 2 | Apr 3, 2023 | clinicaltrials |
| NCT05539833 | KSH01-TCRT Solid Tumors(KSH01-TCRT) | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05580796 | KSH01-R02-101 Solid Tumors | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05766527 | A Study of KM602 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 38 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT04495790 | AIMS Cancer Outcomes Study(ACOS) | recruiting | — | 500 | Advanced Integrative Medical Science InstituteOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05539768 | Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 8 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Sep 14, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05320588 | A Study in Patients With Advanced Cancers | recruiting | Phase 1 / Phase 2 | 332 | BiOneCure Therapeutics Inc.INDUSTRY | 1 | Jul 19, 2022 | clinicaltrials |
| NCT05392699 | ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy | recruiting | Phase 1 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05320874 | A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. | not yet recruiting | Phase 1 | 232 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 11, 2022 | clinicaltrials |
| NCT04475705 | Propofol vs Sevo for Paediatric Tumor Surgery | recruiting | Phase 4 | 100 | Hong Kong Children's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03865082 | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | active not recruiting | Phase 2 | 30 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05166070 | An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | recruiting | Early Phase 1 | 24 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT02884375 | Elderly CAncer Patient(ELCAPA) | recruiting | — | 3,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02446431 | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence(Metronomic) | recruiting | Early Phase 1 | 20 | Miller Children's & Women's Hospital Long BeachOTHER | 1 | May 18, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Nov 27, 2023source: clinicaltrials